Allergy Therapeutics (AGY)

 

Latest News

Grant of Awards under Long Term Incentive Plan

RNS Number: 0414I Allergy Therapeutics PLC 16 March 2018 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Grant of Awards under Long Term Incentive Plan Allergy Therapeutics (AIM:AGY), the fully integrated pharmaceutical company specialising in allergy vaccines, announces that, pursuant to the Company's Long Term Incentive Plan ("LTI...

Director/PDMR Shareholding

RNS Number: 0170I Allergy Therapeutics PLC 16 March 2018 16 March 2018 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Company") Director/PDMR Shareholding Allergy Therapeutics (AIM:AGY) , the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that, on 15 March 2018, Tunde Otulana, Non-Executive Dir...

Allergy Therapeutics losses narrow during 'abnormally weak' pollen season

Allergy Therapeutics posted a moderately lower first-half loss after a rise in revenue was offset by higher expenses. Pre-tax...

Hardman: Clinical development towards submission

RNS Number: 8865G Allergy Therapeutics PLC 07 March 2018 Hardman Research: Clinical development towards submission Clinical development towards submission: AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) Grass, the subcutaneous allergy immunotherapy (AIT), continues to gain market share d...

All News

DateHeadlineSource
16-03-18Grant of Awards under Long Term Incentive PlanRNS
16-03-18Director/PDMR ShareholdingRNS
07-03-18Allergy Therapeutics losses narrow during 'abnormally weak' pollen seasonStockMarketWire
07-03-18Hardman: Clinical development towards submissionRNS
07-03-18Interim ResultsRNS
28-02-18Polyvac? Peanut CMO appointedRNS
15-02-18Allergy Therapeutics to present on 7 March 2018 at the Shares and AJ Bell Spotlight Evening in LondonStockMarketWire
12-02-18Allergy completes recruitment in grass allergy study, results due ahead of expectationsStockMarketWire
12-02-18Completion of recruitment in PQ Grass Ph II trialRNS
02-02-18Hardman Research: Growth in a tough marketRNS
31-01-18Allergy Therapeutics first-half revenue rises 4.4%StockMarketWire
31-01-18Trading UpdateRNS
10-01-18Holdings in CompanyRNS
09-01-18Allergy Therapeutics completes recruitment for clinical study StockMarketWire
09-01-18PQ Birch Phase III trial completes recruitmentRNS
12-12-17Allergy Therapeutics co-development agreement with Ergomed StockMarketWire
12-12-17Co-development agreement with Ergomed plcRNS
07-12-17Holding(s) in CompanyRNS
22-11-17All resolutions passed at AGM of Allergy TherapeuticsStockMarketWire
22-11-17Result of AGMRNS
21-11-17Block Listing ApplicationRNS
13-11-17Allergy Therapeutics to Present at Jefferies 2017RNS
07-11-17Director/PDMR ShareholdingRNS
07-11-17Director/PDMR ShareholdingRNS
19-10-17Publication of Annual Report and notice of AGMRNS
19-10-17Allergy Therapeutics starts dosing for grass pollen trial StockMarketWire
19-10-17Commencement of dosing in PQ Grass Phase II TrialRNS
12-10-17Holding(s) in CompanyRNS
12-10-17Director Deals - Allergy Therapeutics PLC (AGY)StockMarketWire
12-10-17Director/PDMR ShareholdingRNS
10-10-17Allergy Therapeutics 'continuing to gain market share'StockMarketWire
10-10-17Hardman Research: Continuing to gain market shareRNS
28-09-17Broker Forecast - finnCap issues a broker note on Allergy Therapeutics PLCStockMarketWire
28-09-17Allergy Therapeutics pre-tax losses narrow StockMarketWire
28-09-17Preliminary ResultsRNS
18-09-17Allergy Therapeutics gets approval for PQ Grass trial StockMarketWire
18-09-17Approval for PQ Grass Phase II trialRNS
11-09-17Allergy Therapeutics expands R&D and clinical team StockMarketWire
11-09-17Expansion of Clinical Development and R&D teamsRNS
15-08-17 Allergy Therapeutics schedules FY results StockMarketWire

RSS feeds

  • Editorial news feed for LSE:AGY Editorial
  • Regulatory news feed for LSE:AGY Regulatory